MMV371 / J&J, Medicines for Malaria Venture - LARVOL DELTA

MV371 LAI FiH: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Medicines for Malaria Venture | N=24 ➔ 32

Enrollment change • First-in-human • Infectious Disease • Malaria

Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Medicines for Malaria Venture

New P1 trial • Infectious Disease • Malaria

Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations. (PubMed, Infection) - "The Medicines for Malaria Venture (MMV) has contributed significantly to the drug pipeline, developing candidates like Z439, KAF156, MMV371, MMV055/167, INE963 and GSK701. These multifaceted advancements may support sustained malaria control efforts and complement broader eradication strategies. This review underscores the need for integrated, multidisciplinary strategies and opportunities to advance malaria eradication efforts globally."

Journal • Review • Infectious Disease • Malaria

MV371 LAI FiH: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Medicines for Malaria Venture | Recruiting ➔ Completed

First-in-human • Trial completion • Infectious Disease • Malaria

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Medicines for Malaria Venture | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Medicines for Malaria Venture

New P1 trial • Infectious Disease • Malaria

MV371 LAI FiH: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Medicines for Malaria Venture | Trial completion date: Mar 2025 ➔ Aug 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

MV371 LAI FiH: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Medicines for Malaria Venture | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

MV371 LAI FiH: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Medicines for Malaria Venture

New P1 trial • Infectious Disease • Malaria